Possible prediction of underlying lymphoma by high sIL-2R/ferritin ratio in hemophagocytic syndrome

被引:64
作者
Tabata, Chiharu [2 ]
Tabata, Rie [1 ]
机构
[1] Hyogo Prefectural Tsukaguchi Hosp, Dept Internal Med, Amagasaki, Hyogo 6610012, Japan
[2] Hyogo Coll Med, Div Resp Med, Dept Internal Med, Nishinomiya, Hyogo, Japan
关键词
Ferritin; Hemophagocytic syndrome; Malignant lymphoma; Soluble IL-2 receptor; B-CELL LYMPHOMA; SOLUBLE INTERLEUKIN-2 RECEPTOR; SERUM; HYPERCYTOKINEMIA; GUIDELINES; FERRITIN; MARKER;
D O I
10.1007/s00277-011-1239-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In some instances, because of the lack of mass formation and the absence of prominent lymph node enlargement, diagnosis of lymphoma-associated hemophagocytic syndrome (LAHS) is difficult, which results in the development of progressive disease with unfavorable prognosis. Therefore, in the diagnosis of secondary hemophagocytic syndrome (HPS), markers for underlying malignant lymphoma are required. We reviewed 110 Japanese patients, including 57 LAHS cases and 53 benign disease-associated HPS cases, and demonstrated that the values of the serum sIL-2R level and sIL-2R/ferritin ratio in LAHS patients were both statistically higher than those of patients with benign disease-associated HPS. Most LAHS patients showed high values of both indices. The positive predictive value of patients showing high values of both indices for LAHS was 95.6%. On the other hand, the predictive value of patients showing low values of both indices for benign disease-associated HPS was 92.1%. We propose serum sIL-2R/ferritin ratio as a novel useful marker for predicting underlying malignant lymphoma in HPS patients.
引用
收藏
页码:63 / 71
页数:9
相关论文
共 30 条
  • [1] EXPRESSION OF TRANSFERRIN RECEPTORS AND INTRACELLULAR FERRITIN DURING TERMINAL DIFFERENTIATION OF HUMAN-MONOCYTES
    ANDREESEN, R
    OSTERHOLZ, J
    BODEMANN, H
    BROSS, KJ
    COSTABEL, U
    LOHR, GW
    [J]. BLUT, 1984, 49 (03): : 195 - 202
  • [2] Disseminated intravascular B-cell lymphoma: Clinicopathological features and outcome of three cases treated with anthracycline-based immunochernotherapy
    Bouzani, Maria
    Karmiris, Themis
    Rontogianni, Dimitra
    Delimpassi, Susanna
    Apostolidis, John
    Mpakiri, Maria
    Nikiforakis, Emmanuel
    [J]. ONCOLOGIST, 2006, 11 (08) : 923 - 928
  • [3] ESUMI N, 1988, CANCER-AM CANCER SOC, V61, P2071, DOI 10.1002/1097-0142(19880515)61:10<2071::AID-CNCR2820611023>3.0.CO
  • [4] 2-6
  • [5] FUJIWARA F, 1993, AM J PEDIAT HEMATOL, V15, P92
  • [6] HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
    Henter, Jan-Inge
    Horne, AnnaCarin
    Arico, Maurizio
    Egeler, R. Maarten
    Filipovich, Alexandra H.
    Imashuku, Shinsaku
    Ladisch, Stephan
    McClain, Ken
    Webb, David
    Winiarski, Jacek
    Janka, Gritta
    [J]. PEDIATRIC BLOOD & CANCER, 2007, 48 (02) : 124 - 131
  • [7] HYPERCYTOKINEMIA IN FAMILIAL HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
    HENTER, JI
    ELINDER, G
    SODER, O
    HANSSON, M
    ANDERSSON, B
    ANDERSSON, U
    [J]. BLOOD, 1991, 78 (11) : 2918 - 2922
  • [8] HENTER JI, 1991, SEMIN ONCOL, V18, P29
  • [9] SOLUBLE INTERLEUKIN-9 RECEPTOR - A USEFUL PROGNOSTIC FACTOR FOR PATIENTS WITH HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
    IMASHUKU, S
    HIBI, S
    SAKO, M
    ISHIDA, Y
    MUGISHIMA, H
    CHEN, JM
    TSUNEMATSU, Y
    [J]. BLOOD, 1995, 86 (12) : 4706 - 4707
  • [10] Nationwide survey of hemophagocytic lymphohistiocytosis in Japan
    Ishii, Eiichi
    Ohga, Shouichi
    Imashuku, Shinsaku
    Yasukawa, Masaki
    Tsuda, Hiroyuki
    Miura, Ikuo
    Yamamoto, Ken
    Horiuchi, Hisanori
    Takada, Kenzo
    Ohshima, Koichi
    Nakamura, Shigeo
    Kinukawa, Naoko
    Oshimi, Kazuo
    Kawa, Keisei
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2007, 86 (01) : 58 - 65